PTC Therapeutics (PTCT) Misses Q4 EPS by 78c; Offers FY23 Guidance

PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($2.35), $0.78 worse than the analyst estimate of ($1.57). Revenue for the quarter came in at $167.4 million versus the consensus estimate of $190.38 million.

GUIDANCE:

PTC Therapeutics sees FY2023 revenue of $0.94-1 billion, versus the consensus of $0.9 billion.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Carnival shares drop despite earnings beat on weak guidance